Revvity Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Revvity ha aumentado sus beneficios a una tasa media anual de 6.6%, mientras que los beneficios de la industria de Life Sciences han experimentado un crecimiento de 16.4% anual. Los ingresos han ido creciendo a una tasa media de 2.2% al año. La rentabilidad financiera de Revvity es de 2.3%, y sus márgenes netos son de 6.5%.

Información clave

0.4%

Tasa de crecimiento de los beneficios

-1.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Life Sciences	21.5%
Tasa de crecimiento de los ingresos	0.5%
Rentabilidad financiera	2.3%
Margen neto	6.7%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Investors Can Find Comfort In Revvity's (NYSE:RVTY) Earnings Quality

Feb 13

Recent updates

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 49% Undervalued

Jan 04

Revvity: More Than A Name Change Is Needed For PerkinElmer

Dec 29

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Dec 20

Is Revvity (NYSE:RVTY) Using Too Much Debt?

Oct 07

Revvity: Recent Investments, Acquisitions, Not Pulling Economic Weight (Rating Downgrade)

Oct 04

At US$108, Is Revvity, Inc. (NYSE:RVTY) Worth Looking At Closely?

Sep 22

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 40% Undervalued

Aug 17

Revvity: New Name - But New Investment Outlook? Reiterate Buy

Jul 18

Revvity (NYSE:RVTY) Seems To Use Debt Quite Sensibly

Jul 03

What Does Revvity, Inc.'s (NYSE:RVTY) Share Price Indicate?

Jun 17

Calculating The Fair Value Of Revvity, Inc. (NYSE:PKI)

May 16

We Think PerkinElmer (NYSE:PKI) Can Stay On Top Of Its Debt

Mar 28

When Should You Buy PerkinElmer, Inc. (NYSE:PKI)?

Mar 13

PerkinElmer Q4 2022 Earnings Preview

Feb 13

A Look At The Intrinsic Value Of PerkinElmer, Inc. (NYSE:PKI)

Feb 10

PerkinElmer: Capital Budgeting A Key Factor To The Investment Debate

Jan 31

Danaher earnings weigh on other life sciences tools, services companies

Jan 24

PerkinElmer says Q4 results will meet or exceed prior guidance

Jan 09

PerkinElmer (NYSE:PKI) Has A Pretty Healthy Balance Sheet

Dec 27

Is It Time To Consider Buying PerkinElmer, Inc. (NYSE:PKI)?

Dec 12

PerkinElmer receives FDA approval for EONIS assay for spinal muscular atrophy in newborns

Nov 14

PerkinElmer reports mixed Q3 earnings, initiates Q4 and updates FY22 pro forma guidance

Nov 08

PerkinElmer, Inc.'s (NYSE:PKI) Intrinsic Value Is Potentially 48% Above Its Share Price

Oct 28

PerkinElmer declares $0.07 dividend

Oct 27

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Revvity. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NYSE:RVTY Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	2,726	183	960	210
31 Dec 23	2,751	180	942	217
01 Oct 23	2,796	213	923	217
02 Jul 23	2,837	250	927	217
02 Apr 23	3,024	353	942	216
01 Jan 23	3,312	513	940	222
02 Oct 22	3,599	599	1,001	222
03 Jul 22	3,748	637	989	219
03 Apr 22	3,483	694	885	195
02 Jan 22	3,828	889	854	200
03 Oct 21	4,155	1,086	893	197
04 Jul 21	4,257	1,155	893	197
04 Apr 21	4,438	1,074	961	217
03 Jan 21	2,663	631	729	146
04 Oct 20	3,234	412	887	196
05 Jul 20	2,977	294	866	191
05 Apr 20	2,887	226	845	190
29 Dec 19	2,884	228	833	189
29 Sep 19	2,835	235	806	194
30 Jun 19	2,802	251	794	197
31 Mar 19	2,783	247	790	196
30 Dec 18	2,778	237	809	194
30 Sep 18	2,663	128	761	180
01 Jul 18	2,543	149	719	166
01 Apr 18	2,387	147	667	152
31 Dec 17	2,257	157	615	139
01 Oct 17	2,182	258	587	135
02 Jul 17	2,142	215	580	129
02 Apr 17	2,132	210	584	128
01 Jan 17	2,116	216	585	124
02 Oct 16	1,999	198	574	108
03 Jul 16	2,048	199	583	110
03 Apr 16	2,076	190	583	110
03 Jan 16	2,105	189	586	113
04 Oct 15	2,263	176	661	127
28 Jun 15	2,241	164	657	126
29 Mar 15	2,234	167	656	124
28 Dec 14	2,070	130	648	108
28 Sep 14	2,221	203	576	123
29 Jun 14	2,201	201	577	124
30 Mar 14	2,185	176	579	128
29 Dec 13	2,158	174	581	132
29 Sep 13	2,139	85	622	133
30 Jun 13	2,126	73	627	134

Ingresos de calidad: RVTY tiene un gran one-off loss de $157.9M impacto en sus últimos 12 meses de resultados financieros a 31st December, 2023.

Margen de beneficios creciente: Los actuales márgenes de beneficio(6.5%) de RVTY son inferiores a los del año pasado (15.5%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de RVTY han crecido un 6.6% al año en los últimos 5 años.

Acelerando crecimiento: RVTY ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: RVTY tuvo un crecimiento negativo de los beneficios (-65.1%) durante el año pasado, lo que dificulta la comparación con la media de la industria Life Sciences (-6.6%).

Revvity Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: EPS misses analyst expectations

Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Investors Can Find Comfort In Revvity's (NYSE:RVTY) Earnings Quality

Full year 2023 earnings: EPS exceeds analyst expectations

Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Recent updates

First quarter 2024 earnings: EPS misses analyst expectations

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Dividend of US$0.07 announced

Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024

Revvity Unveils A New Era of Automated Tuberculosis Testing

Upcoming dividend of US$0.07 per share

Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Revvity: Enter Now As Reorganization Takes Shape

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research

We Think Revvity (NYSE:RVTY) Can Stay On Top Of Its Debt

Investors Can Find Comfort In Revvity's (NYSE:RVTY) Earnings Quality

Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

CEO, President & Director notifies of intention to sell stock

New minor risk - Earnings quality

Price target increased by 8.9% to US$122

Revvity Showcases Cutting-Edge Solutions at SLAS2024

Full year 2023 earnings: EPS exceeds analyst expectations

Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024

Dividend of US$0.07 announced

Revvity, Inc., Annual General Meeting, Apr 23, 2024

Revvity, Inc. Announces Board Elections, Effective February 1, 2024

Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now?

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024

Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 49% Undervalued

Revvity: More Than A Name Change Is Needed For PerkinElmer

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Consensus EPS estimates fall by 15%

Price target decreased by 22% to US$107

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Is Revvity (NYSE:RVTY) Using Too Much Debt?

Revvity: Recent Investments, Acquisitions, Not Pulling Economic Weight (Rating Downgrade)

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

At US$108, Is Revvity, Inc. (NYSE:RVTY) Worth Looking At Closely?

Revvity, Inc. Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 40% Undervalued

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Earnings quality

Second quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued after recent price drop

Revvity Declares Quarterly Dividend, Payable on November 10, 2023

Revvity: New Name - But New Investment Outlook? Reiterate Buy

Revvity, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Upcoming dividend of US$0.07 per share at 0.2% yield

Revvity (NYSE:RVTY) Seems To Use Debt Quite Sensibly

Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research

Now 22% undervalued after recent price drop

What Does Revvity, Inc.'s (NYSE:RVTY) Share Price Indicate?

Revvity, Inc. Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development

Calculating The Fair Value Of Revvity, Inc. (NYSE:PKI)

Consensus EPS estimates increase by 42%, revenue downgraded

Revvity, Inc. (NYSE:PKI) announces an Equity Buyback for $600 million worth of its shares.

First quarter 2023 earnings: EPS exceeds analyst expectations

Insider notifies of intention to sell stock

Upcoming dividend of US$0.07 per share at 0.2% yield

Insufficient new directors

We Think PerkinElmer (NYSE:PKI) Can Stay On Top Of Its Debt

Insider notifies of intention to sell stock

Desglose de ingresos y gastos
Beta